NRX Pharmaceuticals, Inc. (NRXP): Cash & Equivalents
$7.80M
As of 2025-12-31
$26.69M
As of 2026-06-30
-27.0%
3-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $7.80M | +440.3% | 2026-03-23, Balance as of period end |
| 2024-12-31 | $1.44M | -68.6% | 2026-03-23, Balance as of period end |
| 2023-12-31 | $4.59M | -77.1% | 2025-03-14, Balance as of period end |
| 2022-12-31 | $20.05M | -27.4% | 2024-03-29, Balance as of period end |
| 2021-12-31 | $27.61M | n/a | 2023-03-31, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| NRX Pharmaceuticals, Inc. (NRXP) | 2025-12-31 | $7.80M | +440.3% |
| Avenue Therapeutics, Inc. (ATXI) | 2025-12-31 | $2.85M | +10.1% |
| Northwest Biotherapeutics Inc (NWBO) | 2025-12-31 | $3.04M | +39.8% |
| Cannapharmarx, Inc. (CPMD) | 2025-12-31 | $1.8K | -16.3% |
| Rani Therapeutics Holdings, Inc. (RANI) | 2025-12-31 | $18.62M | +394.9% |
| IGC Pharma, Inc. (IGC) | 2025-03-31 | $405.0K | -66.2% |
| Vistagen Therapeutics, Inc. (VTGN) | 2026-03-31 | $30.79M | -54.1% |
| Longeveron Inc. (LGVN) | 2025-12-31 | $4.66M | -75.8% |
| Neuphoria Therapeutics Inc. (NEUP) | 2026-06-30 | $19.87M | +39.8% |
Compare NRXP, ATXI, NWBO, CPMD side by side · Screen every company in Pharmaceutical Preparations ↗